Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects

Sebastian Zundler(Universitätsklinikum Erlangen), Britta Siegmund(Humboldt-Universität zu Berlin)

Frontiers in Immunology

July 28, 2017

10.3389/fimmu.2017.00891

Cited by 69

Related Papers

Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans

|Cell|2019|472

Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD

|Inflammatory Bowel Diseases|2015|361

An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease

|Gastroenterology|2021|94

Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study

|Journal of Crohn s and Colitis|2025|10

P0636 Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study

|Journal of Crohn s and Colitis|2025|1